The company said, “The reduction in revenue between Quarter 4, 2024 and Quarter 4, 2025 was primarily driven by:The residual impact of the disruption to the global health market for HIV testing in 2025 due to changes affecting international aid funding structures, and The fine-tuning of manufacturing and supply-chain processes to accommodate the rise in demand for TrinScreen HIV in late 2025 as the Company transitioned to outsourced manufacturing under the Company’s Comprehensive Transformation Plan.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Sets Up $25 Million Standby Equity Facility to Fund Growth
- Trinity Biotech files to sell 35.28M American Depositary Shares for holders
- Trinity Biotech secures $25M standby equity purchase agreement
- Trinity Biotech Warned by Nasdaq Over Minimum Public Float Value
- Trinity Biotech receives noncompliance notification from Nasdaq